Here we further presented that I-BET151 harbored the inhibitory effect on inflammatory cytokine secretion and osteoclast formation in MM, altogether demonstrating that the inhibition of BRD4 could be a promising strategy for the treatment of lytic bone disorders. The gene discussed is BRD4; the disease is bone disorder.